Article Information
History
- May 29, 2024.
Article Versions
- Version 1 (May 27, 2024 - 19:48).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Alind Gupta1,*,
- Kelvin Chan4,
- Manuel Gomes2,
- Stephen Duffield3,
- Sreeram Ramagopalan6,
- Seamus Kent5,
- Vivek Subbiah8,
- Winson Cheung9,
- Eran Bendavid7 and
- Paul Arora10
- 1Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Canada
- 2Department of Applied Health Research, University College London, UK
- 3National Institute for Health and Care Excellence (NICE), UK
- 4Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Canada
- 5Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Netherlands
- 6Centre for Pharmaceutical Medicine Research, King’s College London, UK
- 7Division of Primary Care and Population Health, Department of Medicine, Stanford University, USA
- 8Sarah Cannon Research Institute, USA
- 9Department of Community Health Sciences, University of Calgary, Canada; Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Canada
- 10Dalla Lana School of Public Health, University of Toronto, Canada
- ↵* Corresponding author; email: alind.gupta{at}utoronto.ca
Posted May 29, 2024.
Transportability of patient outcomes from a US clinical trial to real-world populations - a case study using Lung-MAP S1400I (NCT02785952)
